Search Results | MSF Science Portal

Journal Article

|

Editorial

Kuksa L, Andrejak C, Haecker B, Bothamley G, Calcagno A, et al.

2025-03-01 • IJTLD OPEN

Pretomanid is a key anti-TB drug included in the WHO list of essential medications. The current EMA-approve...

Journal Article

|

Research

Sweeney S, Laurence YV, Berry C, Singh MP, Dodd M, et al.

2025-02-01 • Lancet Global Health

BACKGROUND

New 6-month rifampicin-resistant tuberculosis treatment regimens containing bedaquiline, pretomanid, and linezolid (BPaL) with or without moxifloxaci...

Journal Article

|

Research

Guglielmetti L, Khan U, Velásquez GE, Gouillou M, Abubakirov A, et al.

2025-01-29 • New England Journal of Medicine

BACKGROUND

For decades, poor treatment options and low-quality evidence plagued care for patients with rifampin-resistant tuberculosis. The advent of new drugs ...

Journal Article

|

Research

Motta I, Cusinato M, Ludman AJ, Lachenal N, Dodd M, et al.

2024-06-06 • Antimicrobial Agents and Chemotherapy

Regimens for the treatment of rifampicin-resistant tuberculosis currently rely on the use of QT-prolonging agents. Using data from the randomized controlled trial, TB-PRACTECAL, we inves...

Conference Material

|

Slide Presentation

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

Conference Material

|

Abstract

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Lachenal N, et al.

2024-05-16 • MSF Scientific Day International 2024

INTRODUCTION
Tuberculosis (TB) is a major public health challenge encountered across many Médecins Sans Frontières (MSF) fields. Management of drug-resistant TB is an operational pri...

Journal Article

|

Review

Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, et al.

2024-03-20 • Clinical Infectious Diseases

BACKGROUND
Effectiveness, safety, tolerability, and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel 6-month oral regimens that include ...

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2024-02-01 • Lancet Respiratory Medicine

BACKGROUND
Around 500,000 people worldwide develop rifampicin-resistant tuberculosis each year. The proportion of successful treatment outcomes remains low and new treatments are nee...

Journal Article

|

Research

Guglielmetti L, Khan U, Velasquez GE, Gouillou M, Abubakirov A, et al.

2024-01-29 • medRxiv

BACKGROUND

Aft...

Journal Article

|

Research

du Cros PAK, Greig J, Cross GB, Cousins C, Berry C, et al.

2023-12-01 • International Journal of Tuberculosis and Lung Disease

BACKGROUND
The value, speed of completion and robustness of the evidence generated by TB treatment trials could be improved by implementing standards for best practice.

METH...

Journal Article

|

Research

Hasan T, Medcalf E, Nyang'wa BT, Egizi E, Berry C, et al.

2023-10-24 • Clinical Infectious Diseases

BACKGROUND
Effectiveness, safety, tolerability and adherence are critical considerations in shifting to shorter tuberculosis (TB) regimens. Novel six-month oral regimens that include...

Journal Article

|

Review

Motta I, Boeree M, Chesov D, Dheda K, Günther G, et al.

2023-07-21 • Clinical Microbiology and Infection

BACKGROUND
Tuberculosis is a global health challenge and one of the leading causes of death worldwide. In the last decade, the tuberculosis treatment landscape has dramatically chang...

Conference Material

|

Poster

Motta I, Cusinato M, Ludman A, Abdrasuliev T, Butabekov I, et al.

2023-06-07 • MSF Scientific Day International 2023

Journal Article

|

Research

Nyang'wa BT, Berry C, Kazounis E, Motta I, Parpieva N, et al.

2022-12-22 • New England Journal of Medicine

BACKGROUND
In patients with rifampin-resistant tuberculosis, all-oral treatment regimens that are more effective, shorter, and have a more acceptable side-effect profile than current...

Journal Article

|

Research

Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, et al.

2022-12-07 • PLOS Global Public Health

Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PR...

Journal Article

|

Pre-Print

Sweeney S, Berry C, Kazounis E, Motta I, Vassall A, et al.

2022-11-10 • medRxiv

INTRODUCTION
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent eviden...

Conference Material

|

Video

Berry C, Motta I, Kazounis E, Fielding K, Dodd M, et al.

2022-06-07 • MSF Scientific Days International 2022

No abstract available.

Conference Material

|

Slide Presentation

Nyang'wa BT, Berry C, Motta I, Kazounis E

2021-05-19 • MSF Scientific Days International 2021: Research

Conference Material

|

Slide Presentation

Berry C, Motta I, Kazounis E, Fielding K, Dodd M, et al.

2022-05-11 • MSF Scientific Days International 2022

Journal Article

|

Editorial

Motta I, Cozzi SN, Pontali E

2022-04-01 • International Journal of Tuberculosis and Lung Disease

Science Portal

Urgent request for pretomanid label expansion to align with WHO guidelines and improve treatment accessibility and efficacy

24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation

Oral regimens for rifampin-resistant, fluoroquinolone-susceptible tuberculosis

How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

Improving treatment of multidrug-resistant tuberculosis: Results of the endTB randomised clinical trial

The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid, and linezolid to treat rifampicin-resistant tuberculosis: An individual patient data meta-analysis

Short oral regimens for pulmonary rifampicin-resistant tuberculosis (TB-PRACTECAL): an open-label, randomised, controlled, phase 2B-3, multi-arm, multicentre, non-inferiority trial

Nine-month, all-oral regimens for rifampin-resistant tuberculosis

Standards for clinical trials for treating TB

The safety and tolerability of linezolid in novel short-course regimens containing bedaquiline, pretomanid and linezolid to treat rifampicin-resistant tuberculosis: an individual patient data meta-analysis

Recent advances in the treatment of tuberculosis

ECG findings in BPaL-based TB treatment regimens: the geographical effect on QT prolongation

A 24-week, all-oral regimen for rifampin-resistant tuberculosis

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis

Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis

24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial

Early termination of randomisation into TB-PRACTECAL, a study examining novel six month, all-oral regimens for treatment of drug-resistant tuberculosis

24-week regimens for treatment of rifampicin-resistant tuberculosis: four-arm randomised trial

QT prolongation for old and new drugs: how much should we really worry?